Epub 2021 Aug 31
1 is a single arm phase II trial of weekly carfilzomib, cyclophosphamide and dexamethasone (wKCd), exploring a convenient
The median number of cycles administered was 4 (1-11) cycles
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly
Gay F, Cerrato C, Scalabrini DR, et al
Cyclophosphamide and dexamethasone have been combined with bortezomib (CyBorD et al
1 is a single arm phase II trial of weekly carfilzomib, cyclophosphamide and dexamethasone (wKCd), exploring a convenient
To date, a large proportion of patients present with lenalidomide refractory
Leukemia
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide
Introduction: This phase 1b study evaluated the safety and efficacy of 3 dose levels of carfilzomib when provided with fixed dose oral cyclophosphamide and dexamethasone (KCyd) in patients with newly diagnosed multiple myeloma (MM)
Kyprolis® (carfilzomib) for injection is a proteasome inhibitor used to treat patients with relapsed or refractory multiple myeloma
MUK Five is a phase II open label, randomised, controlled, parallel group, multi-centre trial that will compare the activity of carfilzomib, cyclophosphamide and dexamethasone (CCD) with that of CVD, given over an equivalent treatment period (24 weeks), in participants with multiple myeloma at first relapse, or refractory to no more
Hyperfractionated cyclophosphamide-dexamethasone (hyperCd) with or without carfilzomib and/or daratu- mumab is a potential treatment option for patients with multiple myeloma needing rapid disease control
High risk cytogenetics were defined as the presence of 17p deletion, t(14;16), and/or t(4;14)
Abstract
r
The choice of treatment for patients with multiple myeloma (MM) at first relapse/progression is based on many factors: (1) treatment-related factors, which include the regimen used during first induction, the quality and duration of first response achieved, toxicities from the first treatment, whether the patient underwent autologous stem cell
6%) had dose modification/s, 47 to carfilzomib, 32 to cyclophosphamide and 40 to dexamethasone
Low-dose dexamethasone leads to fewer adverse Background: Proteasome inhibitor (PI)-based induction and consolidation proved to be effective in newly diagnosed multiple myeloma (NDMM) patients (pts) eligible for melphalan 200 mg/m 2-autologous stem cell transplant (MEL200-ASCT)